|
93 Companies |
|
118 Products |
|
118 Products |
|
88 Mechanisms of Action |
|
3 Trials |
|
1622 News |
|
| «12345678910111213...3233» |
- | Victoza (liraglutide) / Novo Nordisk
Trial completion, Enrollment change: Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese (clinicaltrials.gov) - May 3, 2017
P4, N=42, Completed, Sponsor: Universiti Kebangsaan Malaysia Medical Centre
Enrolling by invitation --> Completed | N=60 --> 42
- | Trial completion: Feasibility of Combining Family and Cognitive Therapy to Prevent Chronic Anorexia (clinicaltrials.gov) - Apr 28, 2017
P=N/A, N=30, Completed, Sponsor: Stanford University
Enrolling by invitation --> Completed | N=60 --> 42 Active, not recruiting --> Completed
- | methylprednisolone sodium succinate / Generic mfg.
Clinical: Dexamethasone-induced Hiccup in Chemotherapy Patients Treated by Methylprednisolone Rotation (clinicaltrials.gov) - Apr 28, 2017
P3, N=65, Completed, Sponsor: Chung-Ang University
Active, not recruiting --> Completed N=140 --> 65 | Trial primary completion date: Dec 2014 --> Jun 2016
- | Trial completion, Enrollment change: SAGE: Surveillance Study of Acute Gastroenteritis in Hospitalized Children (clinicaltrials.gov) - Apr 27, 2017
P=N/A, N=198, Completed, Sponsor: Shaikh Ragheb Harb Hospital
N=140 --> 65 | Trial primary completion date: Dec 2014 --> Jun 2016 Active, not recruiting --> Completed | N=150 --> 198
- | Trial completion, Trial primary completion date: FGISP-RCT: Functional Gastrointestinal Disorder Screening Program - A Randomized Controlled Trial (clinicaltrials.gov) - Apr 26, 2017
P=N/A, N=200, Completed, Sponsor: Chinese University of Hong Kong
Active, not recruiting --> Completed | N=150 --> 198 Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> May 2015
- | Trial completion, Enrollment change, Trial primary completion date: Neural Links Between OCD and Anorexia (clinicaltrials.gov) - Apr 25, 2017
P=N/A, N=80, Completed, Sponsor: Stanford University
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> May 2015 Recruiting --> Completed | N=45 --> 80 | Trial primary completion date: Dec 2016 --> Apr 2017
- | escitalopram / Generic mfg.
Trial primary completion date: SSRI Study for Functional Dyspepsia (SS) (clinicaltrials.gov) - Apr 25, 2017
P3, N=72, Recruiting, Sponsor: Chinese University of Hong Kong
Recruiting --> Completed | N=45 --> 80 | Trial primary completion date: Dec 2016 --> Apr 2017 Trial primary completion date: Nov 2015 --> Dec 2017
- |||| ondansetron / Generic mfg., cisplatin / Generic mfg.
Trial completion: Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED) (clinicaltrials.gov) - Apr 23, 2017
P4, N=477, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Nov 2015 --> Dec 2017 No longer recruiting --> Completed
- | esomeprazole / Generic mfg.
Trial primary completion date: BRAVO Study for Functional Dyspepsia (clinicaltrials.gov) - Apr 21, 2017
P4, N=130, Recruiting, Sponsor: Chinese University of Hong Kong
No longer recruiting --> Completed Trial primary completion date: Dec 2015 --> Dec 2017
- | Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma, Sancuso (granisetron) / Solasia
Enrollment change, Trial termination, Trial primary completion date: Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy (clinicaltrials.gov) - Apr 20, 2017
P=N/A, N=29, Terminated, Sponsor: University of Southern California
Trial primary completion date: Dec 2015 --> Dec 2017 N=40 --> 29 | Recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Sep 2017; Lack of Efficacy
- ||||||| cadazolid (ACT-179811) / J&J
Trial completion: Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea (clinicaltrials.gov) - Apr 20, 2017
P3, N=632, Completed, Sponsor: Actelion
N=40 --> 29 | Recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Sep 2017; Lack of Efficacy Active, not recruiting --> Completed
- | aprepitant oral / Generic mfg.
Trial primary completion date: Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents (clinicaltrials.gov) - Apr 19, 2017
P2, N=4, Terminated, Sponsor: The Hospital for Sick Children
Active, not recruiting --> Completed Trial primary completion date: Sep 2018 --> Sep 2016
- | ondansetron / Generic mfg.
Trial completion: OWEP: Ondansetron Administration to WELL Children With Gastroenteritis Associated Vomiting in EDs in Pakistan (clinicaltrials.gov) - Apr 19, 2017
P4, N=625, Completed, Sponsor: Sarah Williamson-Urquhart
Trial primary completion date: Sep 2018 --> Sep 2016 Active, not recruiting --> Completed
- | Enrollment closed, Trial primary completion date: Screening for Fabry Disease in a Pediatric Population at Risk (clinicaltrials.gov) - Apr 17, 2017
P=N/A, N=2000, Active, not recruiting, Sponsor: University Hospital Heidelberg
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Jul 2017
- | Trial completion: Hormonal Therapy for Teens With Anorexia Nervosa (clinicaltrials.gov) - Apr 13, 2017
P3, N=70, Completed, Sponsor: Boston Children’s Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Jul 2017 Active, not recruiting --> Completed
- | Trial completion: Dose-Finding Study of CS19 Expressing ETEC Challenge Strains (clinicaltrials.gov) - Apr 7, 2017
P1, N=25, Completed, Sponsor: Johns Hopkins Bloomberg School of Public Health
Active, not recruiting --> Completed Recruiting --> Completed
- | Trial completion, Trial primary completion date: Guided Self-help for Binge Eating (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=122, Completed, Sponsor: Oxford Health NHS Foundation Trust
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Aug 2017 --> Mar 2017
- | Trial primary completion date: TEDS: Bulimia Nervosa: A Biobehavioral Study (The Eating Disorder Study) (clinicaltrials.gov) - Mar 30, 2017
P=N/A, N=132, Recruiting, Sponsor: Drexel University
Active, not recruiting --> Completed | Trial primary completion date: Aug 2017 --> Mar 2017 Trial primary completion date: May 2016 --> May 2018
- | Phase classification, Trial primary completion date: Alternative Approaches for Nausea Control (clinicaltrials.gov) - Mar 27, 2017
P=N/A, N=252, Recruiting, Sponsor: University of Rochester
Trial primary completion date: May 2016 --> May 2018 Phase classification: P2 --> P=N/A | Trial primary completion date: Feb 2017 --> May 2017
- | Phase classification, Trial primary completion date: Endoscopic Mucosal Resection for the Diagnosis of a-Ganglionosis, a Controlled Prospective Trial (EDGE Trial) (clinicaltrials.gov) - Mar 24, 2017
P=N/A, N=50, Recruiting, Sponsor: Massachusetts General Hospital
Phase classification: P2 --> P=N/A | Trial primary completion date: Feb 2017 --> May 2017 Phase classification: P2 --> P=N/A | Trial primary completion date: Jan 2017 --> Jan 2020
- | Trial initiation date, Trial primary completion date: LACTINEDAP: Limited Abdominal CT in ED Patients With Abdominal Pain (clinicaltrials.gov) - Mar 23, 2017
P=N/A, N=1000, Not yet recruiting, Sponsor: Duke University
Phase classification: P2 --> P=N/A | Trial primary completion date: Jan 2017 --> Jan 2020 Initiation date: May 2016 --> Nov 2017 | Trial primary completion date: May 2018 --> May 2019
- | Trial primary completion date: OLFANOR: Efficacy Study of an Olfactory Stimulation Program for the Recuperation of Autobiographical Memories in Anorexia (clinicaltrials.gov) - Mar 9, 2017
P=N/A, N=100, Recruiting, Sponsor: Lille Catholic University
Initiation date: May 2016 --> Nov 2017 | Trial primary completion date: May 2018 --> May 2019 Trial primary completion date: Jun 2016 --> Jun 2017
- | Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Trial completion, Trial primary completion date: Efficacy of Rifaximin in Preventing Campylobacteriosis (clinicaltrials.gov) - Mar 7, 2017
P2/3, N=28, Completed, Sponsor: Johns Hopkins Bloomberg School of Public Health
Trial primary completion date: Jun 2016 --> Jun 2017 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Aug 2016
- | Trial termination: Dose Ranging Study With the Probiotic Combination (VSL#3) in Diarrhea IBS (clinicaltrials.gov) - Mar 6, 2017
P=N/A, N=180, Terminated, Sponsor: Beth Israel Deaconess Medical Center
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Aug 2016 Active, not recruiting --> Terminated; Lack of enrollment
- ||||| cadazolid (ACT-179811) / J&J
Enrollment closed: Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (clinicaltrials.gov) - Mar 3, 2017
P3, N=631, Active, not recruiting, Sponsor: Actelion
Active, not recruiting --> Terminated; Lack of enrollment Recruiting --> Active, not recruiting
- | morphine sulphate / Generic mfg., ropivacaine / Generic mfg.
Surgery: GR-CWI: Continuous Local Anesthetic and Steroid Infusion in Abdominal Surgery (clinicaltrials.gov) - Mar 3, 2017
P3, N=120, Completed, Sponsor: IRCCS Policlinico S. Matteo
Recruiting --> Active, not recruiting Recruiting --> Completed
- | cyclophosphamide / Generic mfg.
Phase classification: NRR: Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer (clinicaltrials.gov) - Mar 1, 2017
P1, N=19, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Completed Phase classification: P=N/A --> P1
- ||||| cadazolid (ACT-179811) / J&J
Enrollment closed, Trial initiation date: Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea (clinicaltrials.gov) - Mar 1, 2017
P3, N=632, Active, not recruiting, Sponsor: Actelion
Phase classification: P=N/A --> P1 Recruiting --> Active, not recruiting | Initiation date: Nov 2013 --> Mar 2014
- | aprepitant oral / Generic mfg.
Trial primary completion date: Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents (clinicaltrials.gov) - Feb 23, 2017
P2, N=4, Terminated, Sponsor: The Hospital for Sick Children
Recruiting --> Active, not recruiting | Initiation date: Nov 2013 --> Mar 2014 Trial primary completion date: Sep 2016 --> Sep 2018
- | Phase classification: Managing Medication-induced Constipation in Cancer: A Clinical Trial (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=601, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Sep 2016 --> Sep 2018 Phase classification: P1/2 --> P=N/A
- Enrollment change, Trial withdrawal, Trial primary completion date: Metabolic Phenotyping in Anorexia Nervosa (clinicaltrials.gov) - Feb 13, 2017
P=N/A, N=0, Withdrawn, Sponsor: Charite University, Berlin, Germany
Phase classification: P1/2 --> P=N/A N=72 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Apr 2017 --> Aug 2016
- Trial initiation date: Virtual Reality Based Cue-exposure Treatment for Bulimia Nervosa (clinicaltrials.gov) - Feb 9, 2017
P=N/A, N=60, Completed, Sponsor: University of Barcelona
N=72 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Apr 2017 --> Aug 2016 Initiation date: Sep 2014 --> Feb 2015
- Trial completion: Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo (clinicaltrials.gov) - Feb 9, 2017
P=N/A, N=22, Completed, Sponsor: Yale University
Initiation date: Sep 2014 --> Feb 2015 Active, not recruiting --> Completed
- ||||||| Ganaton (itopride) / Abbott
Trial completion, Enrollment change: Long-Term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia (clinicaltrials.gov) - Feb 8, 2017
P3, N=466, Completed, Sponsor: Forest Laboratories
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=300 --> 466
- ||||||| Ganaton (itopride) / Abbott
Trial completion: Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal (clinicaltrials.gov) - Feb 8, 2017
P3, N=500, Completed, Sponsor: Forest Laboratories
Active, not recruiting --> Completed | N=300 --> 466 Active, not recruiting --> Completed
- ||||||| Ganaton (itopride) / Abbott
Trial completion: Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal (clinicaltrials.gov) - Feb 7, 2017
P3, N=645, Completed, Sponsor: Forest Laboratories
Active, not recruiting --> Completed No longer recruiting --> Completed
- ||||||| Ganaton (itopride) / Abbott
Trial completion: Long-term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia (clinicaltrials.gov) - Feb 7, 2017
P3, N=300, Completed, Sponsor: Forest Laboratories
No longer recruiting --> Completed No longer recruiting --> Completed
- |||| Aemcolo (rifamycin SV MMX) / Cosmo Pharma, RedHill, Dr Falk
Trial primary completion date: ERASE: Rifamycin SV-MMX® Tablets Versus Ciprofloxacin Capsules in Acute Traveller's Diarrhoea (clinicaltrials.gov) - Feb 7, 2017
P3, N=776, Active, not recruiting, Sponsor: Dr. Falk Pharma GmbH
No longer recruiting --> Completed Trial primary completion date: Sep 2016 --> Mar 2017
- Rezonic (casopitant) / GSK
Phase classification: An Exploratory Study Examining The Effects Of Taking GW679769 Once-Daily For 4 Days In Patients With Functional Dyspepsia (clinicaltrials.gov) - Feb 7, 2017
P2, N=13, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Sep 2016 --> Mar 2017 Phase classification: P1 --> P2
- | Trial completion, Surgery: Caffeine in the Prevention of Post-operative Nausea and Vomiting (clinicaltrials.gov) - Feb 6, 2017
P=N/A, N=135, Completed, Sponsor: Beth Israel Deaconess Medical Center
Phase classification: P1 --> P2 No longer recruiting --> Completed
- amitriptyline / Generic mfg.
Enrollment change, Trial withdrawal: The Use of L-Carnitine And CoQ10 Supplements In the Treatment of Cyclic Vomiting Syndrome (CVS) (clinicaltrials.gov) - Feb 6, 2017
P=N/A, N=0, Withdrawn, Sponsor: Medical College of Wisconsin
No longer recruiting --> Completed N=500 --> 0 | Enrolling by invitation --> Withdrawn
- celecoxib oral / Generic mfg.
Enrollment change, Trial withdrawal: Celecoxib (Celebrex) in the Management of Acute Renal Colic (clinicaltrials.gov) - Jan 24, 2017
P4, N=0, Withdrawn, Sponsor: University of Minnesota - Clinical and Translational Science Institute
N=500 --> 0 | Enrolling by invitation --> Withdrawn N=57 --> 0 | Terminated --> Withdrawn
- ondansetron / Generic mfg.
Enrollment closed: OWEP: Ondansetron Administration to WELL Children With Gastroenteritis Associated Vomiting in EDs in Pakistan (clinicaltrials.gov) - Jan 23, 2017
P4, N=625, Active, not recruiting, Sponsor: Sarah Williamson-Urquhart
N=57 --> 0 | Terminated --> Withdrawn Recruiting --> Active, not recruiting
- |||| Rezonic (casopitant) / GSK
Trial completion: A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting (clinicaltrials.gov) - Jan 22, 2017
P2, N=701, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting No longer recruiting --> Completed
- Trial completion: TreCogAM: Cognitive Remediation Therapy in Anorexia Nervosa (clinicaltrials.gov) - Jan 17, 2017
P=N/A, N=120, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
No longer recruiting --> Completed Active, not recruiting --> Completed
- ondansetron / Generic mfg.
Trial primary completion date: OSEP: Ondansetron Administration to Children With Gastroenteritis, Vomiting and SOME Dehydration in EDs in Pakistan (clinicaltrials.gov) - Jan 10, 2017
P4, N=868, Recruiting, Sponsor: Sarah Williamson-Urquhart
Active, not recruiting --> Completed Trial primary completion date: Aug 2018 --> Sep 2017
- ondansetron / Generic mfg.
Trial primary completion date: OWEP: Ondansetron Administration to WELL Children With Gastroenteritis Associated Vomiting in EDs in Pakistan (clinicaltrials.gov) - Jan 10, 2017
P4, N=602, Recruiting, Sponsor: Sarah Williamson-Urquhart
Trial primary completion date: Aug 2018 --> Sep 2017 Trial primary completion date: Nov 2016 --> Mar 2017
- Trial suspension, Trial primary completion date: A Trial of Three Types of Enemas Used to Treat Functional Constipation in Children (clinicaltrials.gov) - Jan 9, 2017
P=N/A, N=120, Suspended, Sponsor: Children's Hospital Los Angeles
Trial primary completion date: Nov 2016 --> Mar 2017 Not yet recruiting --> Suspended | Trial primary completion date: Apr 2014 --> Dec 2017
- |||| Acofide (acotiamide) / Zeria, Astellas
P3 data, Trial primary completion date: Phase III, Long-term, Open-label Safety Study of Z-338 (clinicaltrials.gov) - Jan 6, 2017
P3, N=207, Active, not recruiting, Sponsor: Zeria Pharmaceutical
Not yet recruiting --> Suspended | Trial primary completion date: Apr 2014 --> Dec 2017 Trial primary completion date: Feb 2017 --> Nov 2016
- | Trial completion, MRI: MRI and Microbiota Analysis in Constipation (clinicaltrials.gov) - Jan 5, 2017
P=N/A, N=24, Completed, Sponsor: University of Nottingham
Trial primary completion date: Feb 2017 --> Nov 2016 Active, not recruiting --> Completed